A nerve-stimulation study found the share reporting seizure-related hospital stays fell 73% over three years.
LivaNova PLC (LIVN) reported that a 36-month study of its VNS Therapy for Drug-Resistant Epilepsy showed a 73% reduction in seizure-related hospitalizations, improved quality of life, and sustained benefits. The CORE-VNS study, published in Neuromodulation, involved 531 participants across 16 countries, with 426 completing follow-up. The company highlights the therapy's long-term effectiveness and safety.
How this was made
The 30-second read
Why it matters
The data provide concrete evidence of clinical benefit, which could influence physician adoption and payer coverage decisions.
Market read
Positive trial results may lift LivaNova's stock and benefit the broader neurostimulation sector.
What to watch
Reimbursement policies and competition from emerging neuromodulation therapies could temper upside
Background
The CORE‑VNS study is the largest prospective, multinational observational trial of VNS Therapy for drug‑resistant epilepsy, covering 61 sites in 16 countries.
Ticker impact
LivaNova announced 36‑month CORE‑VNS study results showing a 73% drop in seizure‑related hospitalizations.
likely upward pressure as investors price in the clinical success
First disclosure of robust trial outcomes; market typically rewards clear efficacy data for medical‑device firms.
Market effects
strengthens outlook for neurostimulation and epilepsy‑treatment device sector
U.S. and European med‑tech markets may see modest gains
reinforces confidence in long‑term device trials worldwide
Counterpoint
Skeptics may argue that real‑world adoption could lag despite trial success
Key entities
- CompanyLivaNova PLC
Global medical‑technology firm developing VNS Therapy devices.
- ResearcherArjune Sen
Coordinating investigator for the CORE‑VNS study.
